Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 19 de 19
Filtrar
Más filtros











Intervalo de año de publicación
1.
ACS Macro Lett ; 13(3): 288-295, 2024 Mar 19.
Artículo en Inglés | MEDLINE | ID: mdl-38368530

RESUMEN

We report a facile stimuli-responsive strategy to generate reactive oxygen and nitrogen species (ROS and RNS) in the biological milieu from a photocleavable water-soluble block copolymer under visible light irradiation (427 nm, 2.25 mW/cm2). An anthraquinone-based water-soluble polymeric nitric oxide (NO) donor (BCPx-NO) is synthesized, which exhibits NO release in the range of 40-65 µM within 10 h of photoirradiation with a half-life of 30-103 min. Additionally, BCPx-NO produces peroxynitrite (ONOO-) and singlet oxygen (1O2) under photoirradiation. To understand the mechanism of NO release and photolysis of the functional group under blue light, we prepared a small-molecule anthraquinone-based N-nitrosamine (NOD). The cellular investigation of the effect of spatiotemporally controlled ONOO- and 1O2 generation from the NO donor polymeric nanoparticles in a triple negative breast adenocarcinoma (MDA-MB-231) under visible light irradiation (white light, 5.83 mW/cm2; total dose 31.5 J/cm2) showed an IC50 of 0.6 mg/mL. The stimuli-responsive strategy using a photolabile water-soluble block copolymer employed to generate ROS and RNS in a biological setting widens the horizon for their potential in cancer therapy.


Asunto(s)
Neoplasias , Ácido Peroxinitroso , Humanos , Ácido Peroxinitroso/uso terapéutico , Especies Reactivas de Oxígeno/uso terapéutico , Polímeros/uso terapéutico , Especies de Nitrógeno Reactivo/uso terapéutico , Luz , Oxígeno/uso terapéutico , Óxido Nítrico/uso terapéutico , Antraquinonas/uso terapéutico , Neoplasias/tratamiento farmacológico
2.
J Adv Res ; 56: 43-56, 2024 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-36958586

RESUMEN

INTRODUCTION: Chemodynamic therapy (CDT) holds great promise in achieving cancer therapy through Fenton and Fenton-like reactions, which generate highly toxic reactive species. However, CDT is limited by the lower amount of catalyst ions that can decompose already existing intracellular H2O2 and produce reactive oxygen species (ROS) to attain a therapeutic outcome. OBJECTIVES: To overcome these limitations, a tailored approach, which utilizes dual metals cations (Ag+, Fe2+) based silver pentacyanonitrosylferrate or silver nitroprusside (AgNP) were developed for Fenton like reactions that can specifically kill cancer cells by taking advantage of tumor acidic environment without used of any external stimuli. METHODS: A simple solution mixing procedure was used to synthesize AgNP as CDT agent. AgNP were structurally and morphologically characterized, and it was observed that a minimal dose of AgNP is required to destroy cancer cells with limited effects on normal cells. Moreover, comprehensive in vitro studies were conducted to evaluate antitumoral mechanism. RESULTS: AgNP have an effective ability to decompose endogenous H2O2 in cells. The decomposed endogenous H2O2 generates several different types of reactive species (•OH, O2•-) including peroxynitrite (ONOO-) species as apoptotic inducers that kill cancer cells, specifically. Cellular internalization data demonstrated that in short time, AgNP enters in lysosomes, avoid degradation and due to the acidic pH of lysosomes significantly generate high ROS levels. These data are further confirmed by the activation of different oxidative genes. Additionally, we demonstrated the biocompatibility of AgNP on mouse liver and ovarian organoids as an ex vivo model while AgNP showed the therapeutic efficacy on patient derived tumor organoids (PDTO). CONCLUSION: This work demonstrates the therapeutic application of silver nitroprusside as a multiple ROS generator utilizing Fenton like reaction. Thereby, our study exhibits a potential application of CDT against HGSOC (High Grade Serous Ovarian Cancer), a deadly cancer through altering the redox homeostasis.


Asunto(s)
Neoplasias , Plata , Ratones , Animales , Humanos , Especies Reactivas de Oxígeno/metabolismo , Plata/química , Plata/farmacología , Plata/uso terapéutico , Nitroprusiato/farmacología , Nitroprusiato/uso terapéutico , Ácido Peroxinitroso/uso terapéutico , Peróxido de Hidrógeno/química , Neoplasias/tratamiento farmacológico
3.
Anal Biochem ; 682: 115338, 2023 12 01.
Artículo en Inglés | MEDLINE | ID: mdl-37802174

RESUMEN

Osteoarthritis (OA) is the most common type of joint disease, which is difficult to treat, but early standardized diagnosis and treatment can effectively alleviate the pain and symptoms of patients. Therefore, it is important to construct an effective tool to assist in the early diagnosis and evaluation of the therapeutic effect of OA. In this work, a near-infrared (NIR) fluorescence-activated fluorescent probe, YB-1, was constructed for the evaluation of the diagnostic and therapeutic efficacy of OA via detection and imaging of the biomarker of ONOO- in inflammatory cells and mice osteoarthritis models. YB-1 exhibited high selectivity, high sensitivity, and a high ratio yield (I668/I0) fluorescence increasing (∼30 folds). Besides, YB-1 can be used effectively to image endogenous and exogenous ONOO- in living human chondrocytes cells (TC28a2), as well as to evaluate the effect of drug (Chrysosplenol D, CD) treatment in IL-1ß-induced inflammatory cells model. Interestingly, YB-1 was available for OONO- imaging analysis in the collagenase-induced mice OA models and assessment of the effect of CD treatment in mice OA models, with good results. Thus, the newly constructed YB-1 is a powerful molecular tool for the diagnosis and treatment of OA-related diseases.


Asunto(s)
Colorantes Fluorescentes , Osteoartritis , Ratones , Animales , Humanos , Colorantes Fluorescentes/farmacología , Ácido Peroxinitroso/farmacología , Ácido Peroxinitroso/uso terapéutico , Osteoartritis/diagnóstico por imagen , Condrocitos , Diagnóstico por Imagen , Modelos Animales de Enfermedad
4.
Cell Rep Med ; 3(10): 100787, 2022 10 18.
Artículo en Inglés | MEDLINE | ID: mdl-36260983

RESUMEN

A study by Tcyganov et al.1 demonstrates that peroxynitrite, an oxidant abundant in the tumor microenvironment, changes the repertoire of MHC class I peptides presented by tumors and limits immune recognition. Peroxynitrite inhibition in combination with immune checkpoint blockade enhances efficacy preclinically.


Asunto(s)
Evasión Inmune , Neoplasias , Humanos , Ácido Peroxinitroso/uso terapéutico , Inhibidores de Puntos de Control Inmunológico , Antígenos de Neoplasias/uso terapéutico , Antígenos de Histocompatibilidad Clase I , Neoplasias/tratamiento farmacológico , Péptidos/uso terapéutico , Oxidantes/uso terapéutico , Microambiente Tumoral
5.
Angew Chem Int Ed Engl ; 61(40): e202209793, 2022 10 04.
Artículo en Inglés | MEDLINE | ID: mdl-35916871

RESUMEN

Herein, we report an activatable near-infrared (NIR) afterglow theranostic prodrug that circumvents high background noise interference caused by external light excitation. The prodrug can release hydroxycamptothecin (HCPT) in response to the high intratumoral peroxynitrite level associated with immunogenic cell death (ICD), and synchronously activate afterglow signal to monitor the drug release process and cold-to-hot tumor transformation. The prodrug itself is an ICD inducer achieved by photodynamic therapy (PDT). PDT initiates ICD and recruits first-arrived neutrophils to secrete peroxynitrite to trigger HCPT release. Intriguingly, we demonstrate that HCPT can significantly amplify PDT-mediated ICD process. The prodrug thus shows a self-sustainable ICD magnification effect by establishing an "ICD-HCPT release-amplified ICD" cycling loop. In vivo studies demonstrate that the prodrug can eradicate existing tumors and prevent further tumor recurrence through antitumor immune response.


Asunto(s)
Nanopartículas , Neoplasias , Fotoquimioterapia , Profármacos , Línea Celular Tumoral , Humanos , Muerte Celular Inmunogénica , Neoplasias/tratamiento farmacológico , Ácido Peroxinitroso/uso terapéutico , Medicina de Precisión , Profármacos/metabolismo
6.
Sheng Li Xue Bao ; 74(1): 93-109, 2022 Feb 25.
Artículo en Chino | MEDLINE | ID: mdl-35199130

RESUMEN

Diabetic nephropathy is a microvascular complication of diabetes. Its etiology involves metabolic disorder-induced endothelial dysfunction. Endothelium-derived nitric oxide (NO) plays an important role in a number of physiological processes, including glomerular filtration and endothelial protection. NO dysregulation is an important pathogenic basis of diabetic nephropathy. Hyperglycemia and dyslipidemia can lead to oxidative stress, chronic inflammation and insulin resistance, thus affecting NO homeostasis regulated by endothelial nitric oxide synthase (eNOS) and a conglomerate of related proteins and factors. The reaction of NO and superoxide (O2.-) to form peroxynitrite (ONOO-) is the most important pathological NO pathway in diabetic nephropathy. ONOO- is a hyper-reactive oxidant and nitrating agent in vivo which can cause the uncoupling of eNOS. The uncoupled eNOS does not produce NO but produces superoxide. Thus, eNOS uncoupling is a critical contributor of NO dysregulation. Understanding the regulatory mechanism of NO and the effects of various pathological conditions on it could reveal the pathophysiology of diabetic nephropathy, potential drug targets and mechanisms of action. We believe that increasing the stability and activity of eNOS dimers, promoting NO synthesis and increasing NO/ONOO- ratio could guide the development of drugs to treat diabetic nephropathy. We will illustrate these actions with some clinically used drugs as examples in the present review.


Asunto(s)
Diabetes Mellitus , Nefropatías Diabéticas , Nefropatías Diabéticas/tratamiento farmacológico , Endotelio Vascular , Humanos , Óxido Nítrico/metabolismo , Óxido Nítrico Sintasa de Tipo III/metabolismo , Óxido Nítrico Sintasa de Tipo III/farmacología , Óxido Nítrico Sintasa de Tipo III/uso terapéutico , Estrés Oxidativo , Ácido Peroxinitroso/metabolismo , Ácido Peroxinitroso/farmacología , Ácido Peroxinitroso/uso terapéutico
7.
Acta Physiologica Sinica ; (6): 93-109, 2022.
Artículo en Chino | WPRIM (Pacífico Occidental) | ID: wpr-927585

RESUMEN

Diabetic nephropathy is a microvascular complication of diabetes. Its etiology involves metabolic disorder-induced endothelial dysfunction. Endothelium-derived nitric oxide (NO) plays an important role in a number of physiological processes, including glomerular filtration and endothelial protection. NO dysregulation is an important pathogenic basis of diabetic nephropathy. Hyperglycemia and dyslipidemia can lead to oxidative stress, chronic inflammation and insulin resistance, thus affecting NO homeostasis regulated by endothelial nitric oxide synthase (eNOS) and a conglomerate of related proteins and factors. The reaction of NO and superoxide (O2.-) to form peroxynitrite (ONOO-) is the most important pathological NO pathway in diabetic nephropathy. ONOO- is a hyper-reactive oxidant and nitrating agent in vivo which can cause the uncoupling of eNOS. The uncoupled eNOS does not produce NO but produces superoxide. Thus, eNOS uncoupling is a critical contributor of NO dysregulation. Understanding the regulatory mechanism of NO and the effects of various pathological conditions on it could reveal the pathophysiology of diabetic nephropathy, potential drug targets and mechanisms of action. We believe that increasing the stability and activity of eNOS dimers, promoting NO synthesis and increasing NO/ONOO- ratio could guide the development of drugs to treat diabetic nephropathy. We will illustrate these actions with some clinically used drugs as examples in the present review.


Asunto(s)
Humanos , Diabetes Mellitus , Nefropatías Diabéticas/tratamiento farmacológico , Endotelio Vascular , Óxido Nítrico/metabolismo , Óxido Nítrico Sintasa de Tipo III/uso terapéutico , Estrés Oxidativo , Ácido Peroxinitroso/uso terapéutico
8.
Oncol Rep ; 45(5)2021 05.
Artículo en Inglés | MEDLINE | ID: mdl-33760187

RESUMEN

Tumors of the abdominal cavity, such as colorectal, pancreatic and ovarian cancer, frequently metastasize into the peritoneum. Large numbers of metastatic nodules hinder curative surgical resection, necessitating lavage with hyperthermic intraperitoneal chemotherapy (HIPEC). However, HIPEC not only causes severe side effects but also has limited therapeutic efficacy in various instances. At the same time, the age of immunotherapies such as biological agents, checkpoint­ inhibitors or immune­cell therapies, increasingly emphasizes the critical role of anticancer immunity in targeting malignancies. The present study investigated the ability of three types of long­lived reactive species (oxidants) to inactivate cancer cells and potentially complement current HIPEC regimens, as well as to increase tumor cell expression of danger signals that stimulate innate immunity. The human abdominal cancer cell lines HT­29, Panc­01 and SK­OV­3 were exposed to different concentrations of hydrogen peroxide (H2O2), hypochlorous acid (HOCl) and peroxynitrite (ONOO­). Metabolic activity was measured, as well as determination of cell death and danger signal expression levels via flow cytometry and detection of intracellular oxidation via high­content microscopy. Oxidation of tumor decreased intracellular levels of the antioxidant glutathione and induced oxidation in mitochondria, accompanied by a decrease in metabolic activity and an increase in regulated cell death. At similar concentrations, HOCl showed the most potent effects. Non­malignant HaCaT keratinocytes were less affected, suggesting the approach to be selective to some extent. Pro­immunogenic danger molecules were investigated by assessing the expression levels of calreticulin (CRT), and heat­shock protein (HSP)70 and HSP90. CRT expression was greatest following HOCl and ONOO­ treatment, whereas HOCl and H2O2 resulted in the greatest increase in HSP70 and HSP90 expression levels. These results suggested that HOCl may be a promising agent to complement current HIPEC regimens targeting peritoneal carcinomatosis.


Asunto(s)
Alarminas/metabolismo , Ácido Hipocloroso/farmacología , Neoplasias Peritoneales/tratamiento farmacológico , Apoptosis/efectos de los fármacos , Línea Celular Tumoral , Neoplasias Colorrectales/tratamiento farmacológico , Neoplasias Colorrectales/patología , Femenino , Células HaCaT , Humanos , Peróxido de Hidrógeno/farmacología , Peróxido de Hidrógeno/uso terapéutico , Quimioterapia Intraperitoneal Hipertérmica/métodos , Ácido Hipocloroso/uso terapéutico , Mitocondrias/efectos de los fármacos , Mitocondrias/patología , Neoplasias Ováricas/tratamiento farmacológico , Neoplasias Ováricas/patología , Oxidación-Reducción/efectos de los fármacos , Neoplasias Pancreáticas/tratamiento farmacológico , Neoplasias Pancreáticas/patología , Neoplasias Peritoneales/secundario , Peritoneo/efectos de los fármacos , Peritoneo/patología , Ácido Peroxinitroso/farmacología , Ácido Peroxinitroso/uso terapéutico
9.
Angew Chem Int Ed Engl ; 60(9): 4720-4731, 2021 02 23.
Artículo en Inglés | MEDLINE | ID: mdl-33210779

RESUMEN

Photoacoustic (PA) technology can transform light energy into acoustic wave, which can be used for either imaging or therapy that depends on the power density of pulsed laser. Here, we report photosensitizer-free polymeric nanocapsules loaded with nitric oxide (NO) donors, namely NO-NCPs, formulated from NIR light-absorbable amphiphilic polymers and a NO-releasing donor, DETA NONOate. Controlled NO release and nanocapsule dissociation are achieved in acidic lysosomes of cancer cells. More importantly, upon pulsed laser irradiation, the PA cavitation can excite water to generate significant reactive oxygen species (ROS) such as superoxide radical (O2.- ), which further spontaneously reacts with the in situ released NO to burst highly cytotoxic peroxynitrite (ONOO- ) in cancer cells. The resultant ONOO- generation greatly promotes mitochondrial damage and DNA fragmentation to initiate programmed cancer cell death. Apart from PA imaging, PA cavitation can intrinsically amplify reactive species via photosensitization-free materials for promising disease theranostics.


Asunto(s)
Rayos Infrarrojos , Nanocápsulas/química , Ácido Peroxinitroso/química , Polímeros/química , Especies Reactivas de Oxígeno/metabolismo , Animales , Antineoplásicos/química , Antineoplásicos/farmacología , Antineoplásicos/uso terapéutico , Línea Celular Tumoral , Supervivencia Celular/efectos de los fármacos , Clorofilidas , Daño del ADN/efectos de los fármacos , Lisosomas/efectos de los fármacos , Lisosomas/metabolismo , Ratones , Neoplasias/tratamiento farmacológico , Neoplasias/patología , Óxido Nítrico/metabolismo , Donantes de Óxido Nítrico/química , Ácido Peroxinitroso/uso terapéutico , Ácido Peroxinitroso/toxicidad , Técnicas Fotoacústicas , Porfirinas/farmacología , Porfirinas/uso terapéutico , Superóxidos/metabolismo , Nanomedicina Teranóstica , Trasplante Homólogo
10.
CNS Neurosci Ther ; 21(7): 585-90, 2015 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-25996167

RESUMEN

AIM: Hemorrhagic transformation (HT) is a major complication of delayed tissue plasminogen activator (t-PA) treatment in ischemic stroke. We aimed to explore whether peroxynitrite decomposition catalyst (PDC) could prevent such complication. METHODS: Male Sprague-Dawley (SD) rats were subjected to middle cerebral artery occlusion (MCAO) with t-PA (10 mg/kg) or t-PA plus FeTMPyP (3 mg/kg, a representative PDC) at MCAO for 2 or 5 h and reperfusion for 22 or 19 h, respectively. HT was assessed with hemoglobin assay. Neurological deficit was evaluated with Modified Neurological Severity Score (mNSS). Peroxynitrite formation was examined by detecting 3-nitrotyrosine (3-NT) formation. The expression and activity of MMP-9/MMP-2 were assessed by Western blotting and gelatin zymography. RESULTS: t-PA treatment at 2 h of MCAO did not induce HT but attenuated neurological deficit, whereas treatment at 5 h significantly induced HT and worsened the neurological outcome. Such complications were prevented by FeTMPyP cotreatment. Early t-PA treatment inhibited 3-NT and MMP-9/MMP-2 expression, whereas delayed treatment induced 3-NT and MMP-9/MMP-2 expression and activity. FeTMPyP cotreatment downregulated 3-NT and inhibited MMP-9/MMP-2 in both time points. CONCLUSION: Peroxynitrite decomposition catalyst could prevent hemorrhagic transformation and improve neurological outcome ischemic rat brains with delayed t-PA treatment via inhibiting peroxynitrite-mediated MMP activation.


Asunto(s)
Fibrinolíticos/efectos adversos , Hemorragia/inducido químicamente , Hemorragia/tratamiento farmacológico , Hemostáticos/uso terapéutico , Ácido Peroxinitroso/uso terapéutico , Activador de Tejido Plasminógeno/efectos adversos , Animales , Modelos Animales de Enfermedad , Regulación hacia Abajo/efectos de los fármacos , Infarto de la Arteria Cerebral Media/tratamiento farmacológico , Masculino , Metaloproteinasa 2 de la Matriz/metabolismo , Metaloproteinasa 9 de la Matriz/metabolismo , Enfermedades del Sistema Nervioso/etiología , Ratas , Ratas Sprague-Dawley , Reperfusión , Índice de Severidad de la Enfermedad
11.
Transplant Proc ; 41(9): 3603-10, 2009 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-19917352

RESUMEN

BACKGROUND: In an acute kidney transplant rejection rat model, we demonstrated that manganese superoxide dismutase (MnSOD) activity was significantly reduced and MnSOD was nitrated by peroxynitrite (ONOO(-)), resulting in tissue injury. We examined whether tissue injury was reduced after external supplementation of recombinant human MnSOD in a rat renal ischemia-reperfusion injury model. METHODS: Male Brown-Norway rats underwent dissection of the right kidney. The animals were divided into 3 groups. The controls had the left renal blood vessels clamped for 90 minutes to induce ischemia, followed by reperfusion for 16 hours. In the intraperitoneal administration group, MnSOD was administered 30 minutes before ischemia and immediately before reperfusion. In the sham group, neither ischemia nor reperfusion was performed. After reperfusion, blood was collected, the left kidney was dissected and renal function and tissue injury were evaluated. RESULTS: Serum creatinine and K(+), blood urea nitrogen, and aspartate aminotransferase activity decreased significantly, whereas serum Na(+) and renal function improved in the MnSOD group compared with the control and sham groups. On hematoxylin and eosin staining, the histological score indicated that acute tubular necrosis was significantly reduced by MnSOD administration. Periodic acid-Schiff staining was absent in the nonadministration group, whereas it persisted in the MnSOD group. In the proximal renal tubules a large proportion of anti-nitrotyrosine staining was present before but absent after MnSOD administration. CONCLUSIONS: MnSOD administration improved renal function and reduced tissue injury. It may also reduce tissue injury in acute kidney transplant rejection and other tissue injuries caused by similar molecular mechanisms.


Asunto(s)
Riñón/metabolismo , Ácido Peroxinitroso/farmacología , Daño por Reperfusión/prevención & control , Superóxido Dismutasa/uso terapéutico , Animales , Nitrógeno de la Urea Sanguínea , Clonación Molecular , Cartilla de ADN , Modelos Animales de Enfermedad , Humanos , Riñón/efectos de los fármacos , Riñón/patología , Masculino , Nefrectomía , Ácido Peroxinitroso/uso terapéutico , Reacción en Cadena de la Polimerasa , Potasio/sangre , Ratas , Ratas Endogámicas BN , Proteínas Recombinantes/uso terapéutico , Superóxido Dismutasa/genética
12.
J Pharmacol Exp Ther ; 328(3): 777-84, 2009 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-19033557

RESUMEN

Oxidative/nitrative stress caused by peroxynitrite, the reaction product of superoxide (O2(.-)) and nitric oxide (NO), is the primary cause of myocardial ischemia/reperfusion injury. The present study determined whether INO-4885 [5,10,15,20-tetra[N-(benzyl-4'-carboxylate)-2-pyridinium]-21H,23H-porphine iron(III) chloride], a new peroxynitrite decomposition catalyst, may provide cellular protection and protect heart from myocardial ischemia/reperfusion injury. Adult male mice were subjected to 30 min of ischemia and 3 or 24 h of reperfusion. Mice were randomized to receive vehicle, INO-4885 without catalytic moiety, or INO-4885 (3-300 microg/kg i.p.) 10 min before reperfusion. Infarct size, apoptosis, nitrotyrosine content, NO/O2(.-) production, and inducible nitric-oxide synthase (iNOS)/NADPH oxidase expression were determined. INO-4885 treatment reduced ischemia/reperfusion-induced protein nitration and caspase 3 activation in a dose-dependent fashion in the range of 3 to 100 microg/kg. However, doses exceeding 100 microg/kg produced nonspecific effects and attenuated its protective ability. At the optimal dose (30 microg/kg), INO-4885 significantly reduced infarct size (p < 0.01), decreased apoptosis (p < 0.01), and reduced tissue nitrotyrosine content (p < 0.01). As expected, INO-4885 had no effect on ischemia/reperfusion-induced iNOS expression and NO overproduction. To our surprise, this compound significantly reduced superoxide production and partially blocked NADPH oxidase overexpression in the ischemic/reperfused cardiac tissue. Additional experiments demonstrated that INO-4885 provided better cardioprotection than N-(3-(aminomethyl)benzyl)acetamidine (1400W, a selective iNOS inhibitor), apocynin (an NADPH oxidase inhibitor), or Tiron (a cell-permeable superoxide scavenger). Taken together, our data demonstrated that INO-4885 is a cardioprotective molecule that attenuates myocardial reperfusion injury by facilitating peroxynitrite decomposition and inhibiting NADPH oxidase-derived O2(.-) production.


Asunto(s)
Corazón/fisiopatología , Metaloporfirinas/uso terapéutico , Infarto del Miocardio/prevención & control , Ácido Peroxinitroso/uso terapéutico , Daño por Reperfusión/prevención & control , Animales , Apoptosis/efectos de los fármacos , Caspasa 3/metabolismo , Relación Dosis-Respuesta a Droga , Activación Enzimática , Corazón/efectos de los fármacos , Corazón/fisiología , Masculino , Ratones , NADPH Oxidasas/efectos de los fármacos , NADPH Oxidasas/genética , Óxido Nítrico Sintasa de Tipo II/efectos de los fármacos , Óxido Nítrico Sintasa de Tipo II/genética , Estrés Oxidativo/efectos de los fármacos , Estrés Oxidativo/fisiología
14.
Proc Natl Acad Sci U S A ; 105(40): 15511-6, 2008 Oct 07.
Artículo en Inglés | MEDLINE | ID: mdl-18829442

RESUMEN

CNS tissues are protected from circulating cells and factors by the blood-brain barrier (BBB), a specialization of the neurovasculature. Outcomes of the loss of BBB integrity and cell infiltration into CNS tissues can differ vastly. For example, elevated BBB permeability is closely associated with the development of neurological disease in experimental allergic encephalomyelitis (EAE) but not during clearance of the attenuated rabies virus CVS-F3 from the CNS tissues. To probe whether differences in the nature of BBB permeability changes may contribute to the pathogenesis of acute neuroinflammatory disease, we compared the characteristics of BBB permeability changes in mice with EAE and in mice clearing CVS-F3. BBB permeability changes are largely restricted to the cerebellum and spinal cord in both models but differ in the extent of leakage of markers of different size and in the nature of cell accumulation in the CNS tissues. The accumulation in the CNS tissues of CD4 T cells expressing mRNAs specific for IFN-gamma and IL-17 is common to both, but iNOS-positive cells invade into the CNS parenchyma only in EAE. Mice that have been immunized with myelin basic protein (MBP) and infected exhibit the features of EAE. Treatment with the peroxynitrite-dependent radical scavenger urate inhibits the invasion of iNOS-positive cells into the CNS tissues and the development of clinical signs of EAE without preventing the loss of BBB integrity in immunized/infected animals. These findings indicate that BBB permeability changes can occur in the absence of neuropathology provided that cell invasion is restricted.


Asunto(s)
Autoinmunidad , Barrera Hematoencefálica/inmunología , Barrera Hematoencefálica/virología , Sistema Nervioso Central/inmunología , Encefalomielitis Autoinmune Experimental/inmunología , Rabia/inmunología , Animales , Barrera Hematoencefálica/patología , Movimiento Celular , Cerebelo/metabolismo , Encefalomielitis Autoinmune Experimental/metabolismo , Encefalomielitis Autoinmune Experimental/patología , Femenino , Depuradores de Radicales Libres/metabolismo , Inmunohistoquímica , Interferón gamma/inmunología , Interleucina-17/inmunología , Ratones , Ratones Endogámicos , Óxido Nítrico Sintasa/metabolismo , Ácido Peroxinitroso/metabolismo , Ácido Peroxinitroso/uso terapéutico , Rabia/metabolismo , Virus de la Rabia/inmunología , Virus de la Rabia/metabolismo
15.
Diabetes ; 57(4): 889-98, 2008 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-18285558

RESUMEN

OBJECTIVE: Recently we have shown that diabetes-induced retinal neurodegeneration positively correlates with oxidative stress and peroxynitrite. Studies also show that peroxynitrite impairs nerve growth factor (NGF) survival signaling in sensory neurons. However, the causal role of peroxynitrite and the impact of tyrosine nitration on diabetes-induced retinal neurodegeneration and NGF survival signaling have not been elucidated. RESEARCH DESIGN AND METHODS: Expression of NGF and its receptors was examined in retinas from human and streptozotocin-induced diabetic rats and retinal ganglion cells (RGCs). Diabetic animals were treated with FeTPPS (15 mg x kg(-1) x day(-1) ip), which catalytically decomposes peroxynitrite to nitrate. After 4 weeks of diabetes, retinal cell death was determined by TUNEL assay. Lipid peroxidation and nitrotyrosine were determined using MDA assay, immunofluorescence, and Slot-Blot analysis. Expression of NGF and its receptors was determined by enzyme-linked immunosorbent assay (ELISA), real-time PCR, immunoprecipitation, and Western blot analyses. RESULTS: Analyses of retinal neuronal death and NGF showed ninefold and twofold increases, respectively, in diabetic retinas compared with controls. Diabetes also induced increases in lipid peroxidation, nitrotyrosine, and the pro-apoptotic p75(NTR) receptor in human and rat retinas. These effects were associated with tyrosine nitration of the pro-survival TrkA receptor, resulting in diminished phosphorylation of TrkA and its downstream target, Akt. Furthermore, peroxynitrite induced neuronal death, TrkA nitration, and activation of p38 mitogen-activated protein kinase (MAPK) in RGCs, even in the presence of exogenous NGF. FeTPPS prevented tyrosine nitration, restored NGF survival signal, and prevented neuronal death in vitro and in vivo. CONCLUSIONS: Together, these data suggest that diabetes-induced peroxynitrite impairs NGF neuronal survival by nitrating TrkA receptor and enhancing p75(NTR) expression.


Asunto(s)
Diabetes Mellitus Experimental/fisiopatología , Diabetes Mellitus/fisiopatología , Neuropatías Diabéticas/tratamiento farmacológico , Degeneración Nerviosa/prevención & control , Factor de Crecimiento Nervioso/genética , Nervio Óptico/fisiopatología , Ácido Peroxinitroso/uso terapéutico , Animales , Cadáver , Muerte Celular , Diabetes Mellitus/patología , Humanos , Peroxidación de Lípido/efectos de los fármacos , Persona de Mediana Edad , Factor de Crecimiento Nervioso/antagonistas & inhibidores , Nervio Óptico/efectos de los fármacos , Nervio Óptico/patología , ARN Mensajero/genética , Ratas , Valores de Referencia , Células Ganglionares de la Retina/efectos de los fármacos , Células Ganglionares de la Retina/patología , Estreptozocina , Tirosina/análogos & derivados , Tirosina/análisis
16.
Transplantation ; 80(10): 1455-60, 2005 Nov 27.
Artículo en Inglés | MEDLINE | ID: mdl-16340791

RESUMEN

BACKGROUND: Peroxynitrite anions may play a role in normothermic renal ischemia and reperfusion. The purpose of this study was to determine if endogenous peroxynitrite anion is involved in renal preservation injury. METHODS: Experiments were conducted in isolated canine renal tubules and in a canine autotransplant model of hypothermic preservation injury. RESULTS: Isolated renal tubules demonstrated progressive loss of membrane transport function after reperfusion with increasing cold storage times in UW solution as assessed by tetraethylammonium cation transport (TEA). This transport defect was not altered by reperfusion in the presence of WW85, a peroxynitrite decomposition catalyst. Likewise, tubule LDH release was not altered by WW85. Renal tubules did not demonstrate any evidence of peroxynitrite formation after cold storage (0-120 h) or after subsequent reperfusion in vitro as measured by nitrotyrosine adduct formation. Addition of exogenous peroxynitrite (1 mM) directly to freshly isolated renal tubules produced strong nitrotyrosine signals but failed to alter membrane function (TEA uptake). Conversely, SIN-1, a peroxynitrite generator molecule, failed to produce a nitrotyrosine signal in extracted renal tubule proteins but significantly impaired transport function. Finally, function of cold stored canine autografts was not affected by the scavenging of peroxynitrite anions (WW85) before kidney harvest and immediately at reperfusion. Tissue biopsies from cold stored kidney autografts also failed to show evidence of peroxynitrite synthesis either after cold storage (72 h) or after kidney transplantation (60 min reperfusion). CONCLUSIONS: This study concludes that peroxynitrite anions are not formed and are not involved in renal preservation injury.


Asunto(s)
Criopreservación , Riñón , Preservación de Órganos/efectos adversos , Ácido Peroxinitroso/biosíntesis , Daño por Reperfusión/fisiopatología , Animales , Creatinina/sangre , Perros , Riñón/efectos de los fármacos , Riñón/fisiopatología , Trasplante de Riñón , Túbulos Renales/enzimología , L-Lactato Deshidrogenasa/metabolismo , Ácido Peroxinitroso/uso terapéutico , Ácido Peroxinitroso/toxicidad
17.
Pharmacol Res ; 49(1): 7-16, 2004 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-14597146

RESUMEN

The aims of the present study were to investigate the effects of exogenous peroxynitrite (ONOO(-)) on reperfusion arrhythmias in anaesthetized rats, and to detect endogenous and exogenous ONOO(-)-induced chemiluminescence (CL) signals in rat whole blood, which was collected during baseline and in the first minute of reperfusion. ONOO(-) infusion in ischemia/reperfusion (I/R) applied groups caused significant decreases in mean arterial pressure (MAP) and heart rate (HR). Ventricular fibrillation (VF) incidences in the vehicle, ONOO(-), and dec-ONOO(-) infused groups were 63, 100, and 20%, respectively. In control group CL signal was 136+/-34mV during the resting period and was increased to 336+/-57mV with reperfusion. Also, the effects of SOD+CAT, L-NAME and urate were investigated. Ventricular tachycardia (VT) incidence was decreased significantly in SOD+CAT and urate; VF incidence was decreased significantly in SOD+CAT applied groups. CL signals were inhibited with SOD+CAT, L-NAME, and urate. Exogenous ONOO(-) infusion during I/R was also investigated. CL signal in exogenously ONOO(-) infused group is increased 423% during reperfusion. Only urate infused group VF incidence was decreased significantly. CL signals of ONOO(-) infused groups were inhibited by SOD+CAT, L-NAME, and urate. Based on the results of the current study, ONOO(-) seems to be one of the key mediators of reperfusion arrhythmias in anaesthetized rats.


Asunto(s)
Daño por Reperfusión Miocárdica/tratamiento farmacológico , Ácido Peroxinitroso/uso terapéutico , Animales , Presión Sanguínea/efectos de los fármacos , Catalasa/farmacología , Catalasa/uso terapéutico , Esquema de Medicación , Quimioterapia Combinada , Inhibidores Enzimáticos/farmacología , Depuradores de Radicales Libres/farmacología , Frecuencia Cardíaca/efectos de los fármacos , Infusiones Intravenosas , Mediciones Luminiscentes , Masculino , Daño por Reperfusión Miocárdica/complicaciones , Daño por Reperfusión Miocárdica/mortalidad , N-Formilmetionina Leucil-Fenilalanina/farmacología , NG-Nitroarginina Metil Éster/farmacología , Ácido Peroxinitroso/sangre , Ácido Peroxinitroso/química , Ratas , Ratas Wistar , Especies Reactivas de Oxígeno/metabolismo , Superóxido Dismutasa/farmacología , Superóxido Dismutasa/uso terapéutico , Taquicardia Ventricular/complicaciones , Taquicardia Ventricular/tratamiento farmacológico , Taquicardia Ventricular/mortalidad , Ácido Úrico/farmacología , Ácido Úrico/uso terapéutico , Fibrilación Ventricular/complicaciones , Fibrilación Ventricular/tratamiento farmacológico , Fibrilación Ventricular/mortalidad , Visión Ocular/efectos de los fármacos
18.
Ann Neurol ; 54(4): 451-8, 2003 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-14520656

RESUMEN

Hearing loss is the most frequent long-term complication of pneumococcal meningitis, affecting up to 40% of survivors. Unfortunately, adjuvant therapy with dexamethasone has failed to satisfactorily reduce its incidence. Therefore, we evaluated the use of antioxidants for the adjunctive therapy of meningitis-associated deafness. Eighteen hours after intracisternal injection of 7.5 x 10(5) colony-forming units of Streptococcus pneumoniae, rats were treated systemically either with ceftriaxone and the antioxidants and peroxynitrite scavengers Mn(III)tetrakis(4-benzoic acid)-porphyrin (MnTBAP) or N-acetyl-L-cysteine (NAC) or placebo (1 ml phosphate-buffered saline) for 4 days. Hearing was assessed by auditory brainstem response audiometry. Adjunctive antioxidant therapy significantly reduced the long-term hearing loss (14 days after infection) for square wave impulses (mean hearing loss +/- SD: ceftriaxone and placebo, 45+/-26 dB; ceftriaxone and MnTBAP, 9+/-23 dB; ceftriaxone and NAC, 19+/-30 dB) as well as 1 kHz (ceftriaxone and placebo, 28+/-19 dB; ceftriaxone and MnTBAP, 10+/-16 dB; ceftriaxone and NAC, 10+/-17 dB), and 10 kHz tone bursts (ceftriaxone and placebo, 62+/-27 dB; ceftriaxone and MnTBAP, 16+/-13 dB; ceftriaxone and NAC, 25+/-26 dB). Furthermore, both antioxidants attenuated the morphological correlates of meningogenic hearing loss, namely, long-term blood-labyrinth barrier disruption, spiral ganglion neuronal loss, and fibrous obliteration of the perilymphatic spaces. Adjuvant antioxidant therapy is highly otoprotective in meningitis and therefore is a promising future treatment option.


Asunto(s)
Antioxidantes/uso terapéutico , Pérdida Auditiva/prevención & control , Meningitis Neumocócica/complicaciones , Ácido Peroxinitroso/uso terapéutico , Acetilcisteína/uso terapéutico , Animales , Antibacterianos/uso terapéutico , Audiometría , Ceftriaxona/uso terapéutico , Recuento de Células/métodos , Cóclea/efectos de los fármacos , Cóclea/patología , Modelos Animales de Enfermedad , Interacciones Farmacológicas , Azul de Evans/metabolismo , Potenciales Evocados Auditivos del Tronco Encefálico/fisiología , Pérdida Auditiva/etiología , Laberintitis/microbiología , Laberintitis/patología , Masculino , Meningitis Neumocócica/microbiología , Metaloporfirinas/uso terapéutico , Ratas , Ratas Wistar , Ganglio Espiral de la Cóclea/efectos de los fármacos , Ganglio Espiral de la Cóclea/patología , Factores de Tiempo
19.
Eur J Pharmacol ; 449(1-2): 177-81, 2002 Aug 02.
Artículo en Inglés | MEDLINE | ID: mdl-12163122

RESUMEN

We evaluated the effect of different peroxynitrite scavengers for adjunctive therapy of experimental bacterial meningitis. Twenty hours after intracisternal injection of Streptococcus pneumoniae, rats were treated with ceftriaxone [100 mg/kg intraperitoneal (i.p.)] and either urate (300 mg/kg i.p.), Mn(III)tetrakis(4-benzoic acid)porphyrin (MnTBAP, 15 mg/kg i.p.), ascorbate (100 mg/kg i.p.), or urate (300 mg/kg i.p.) + ascorbate (100 mg/kg i.p.). Six hours after initiation of treatment, the cerebrospinal fluid (CSF) pleocytosis was significantly (p<0.05) reduced by urate (8697 +/- 1526 cells/microl) and MnTBAP (8542 +/- 4059 cells/microl) vs. ceftriaxone alone (15,793 +/- 3202 cells/microl). Brain concentrations of proinflammatory cytokines [interleukin-1beta (IL-beta), interleukin-6 (IL-6), and macrophage inflammatory protein-2 (MIP-2)] were also reduced by urate and MnTBAP. The intracranial hypertension was significantly reduced by MnTBAP (14.0 +/- 5.4 mm Hg), but not by urate (25.5 +/- 7.1 mm Hg) vs. ceftriaxone alone (22.5 +/- 5.9 mm Hg). Ascorbate alone had no effect on CSF pleocytosis (15,775 +/- 7058 cells/microl), intracranial pressure (25.6 +/- 8.8 mm Hg), and brain cytokine concentrations. However, the combination of urate and ascorbate was as effective as MnTBAP (CSF pleocytosis: 5392 +/- 4232 cells/microl, intracranial pressure: 13.3 +/- 6.9 mm Hg).


Asunto(s)
Depuradores de Radicales Libres/uso terapéutico , Meningitis Neumocócica/tratamiento farmacológico , Ácido Peroxinitroso/uso terapéutico , Animales , Química Encefálica/efectos de los fármacos , Química Encefálica/fisiología , Ceftriaxona/uso terapéutico , Cefalosporinas/uso terapéutico , Quimiocina CXCL2 , Quimiocinas/metabolismo , Citocinas/metabolismo , Indicadores y Reactivos , Interleucina-1/metabolismo , Interleucina-6/metabolismo , Masculino , Meningitis Neumocócica/líquido cefalorraquídeo , Meningitis Neumocócica/microbiología , Monocinas/metabolismo , Ratas , Ratas Wistar
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA